ArticleReviews in cardiovascular medicine2026
Heart Transplant Outcomes in Chemotherapy-Induced vs. Non-Ischemic-Dilated Cardiomyopathy: Pediatric and Adult Recipients in the Ventricular Assist Device Era.
Article in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy-induced dilated cardiomyopathy (CIDCM) has become an increasingly recognized indication for heart transplantation (HT) among cancer survivors with end-stage heart failure (HF). Advances in cardio-oncology practices, mechanical circulatory support, and refined immunosuppression strategies have improved outcomes; however, comparative data with non-ischemic dilated cardiomyopathy (NIDCM) in the modern ventricular assist device (VAD) era remain limited. Therefore, this study primarily aimed to compare post-transplant outcomes between CIDCM and NIDCM within pediatric and adult cohorts in the VAD era. Methods: Data from the United Network for Organ Sharing (UNOS) registry were used to retrospectively analyze first-time orthotopic HT recipients between January 2010 and March 2023, with follow-up through March 2024. CIDCM was defined using the UNOS diagnosis codes "dilated myopathy-adriamycin" or "dilated myopathy-cancer", whereas NIDCM included idiopathic, familial, myocarditis-related, and other specific DCM subtypes. Primary outcomes were post-HT survival, treated allograft rejection, and new or recurrent malignancy. Results: Among 28,813 recipients, 527 had CIDCM (52 pediatric, 475 adults). Pediatric survival was comparable between groups (1-, 5-, and 10-year survival: 0.92, 0.86, 0.76 vs. 0.95, 0.82, 0.68; Conclusions: HT in CIDCM achieves durable survival and safety comparable to NIDCM. These results support expanding HT eligibility and multidisciplinary evaluation for cancer survivors with advanced HF in the contemporary era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.